相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1986
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers developed an accelerated manufacturing platform using transient electroporation and immunoaffinity purification that reduces HIV vaccine production timelines from 12 months to 4 months while cutting costs by over $500,000. - The platform successfully produced three HIV envelope proteins at 50-80L scale with gram-level yields suitable for Phase I clinical studies, including a stabilized 16055 DG4 NFL trimer currently in human trials. - Comprehensive characterization confirmed the manufactured trimers maintain native-like structure and elicit neutralizing antibodies in preclinical studies, validating this approach for rapid HIV vaccine candidate evaluation.
- The Trump administration has terminated funding for multiple HIV vaccine research programs, including major efforts at Duke Human Vaccine Institute and Scripps Research Institute that have been running since 2012. - Scientists warn the cuts represent a decade-long setback for HIV vaccine development, coming at a critical time when researchers report seeing "light at the end of the tunnel" with promising clinical trial results. - The decision affects 27 separate HIV/AIDS programs totaling $7.5 billion in funding, with HHS citing "duplication of efforts" as justification for prioritizing currently available HIV prevention approaches. - The timing coincides with the FDA's upcoming June 19 decision on lenacapavir, a twice-yearly injectable HIV prevention drug by Gilead Sciences that showed 100% effectiveness in preventing transmission.
